- Trials with a EudraCT protocol (83)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
83 result(s) found for: Hepatic artery.
Displaying page 1 of 5.
EudraCT Number: 2020-005600-19 | Sponsor Protocol Number: APHP200072 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023839-42 | Sponsor Protocol Number: H8O-CY-O027 | Start Date*: 2011-04-29 | ||||||||||||||||
Sponsor Name:General University Hospital in Prague | ||||||||||||||||||
Full Title: EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs | ||||||||||||||||||
Medical condition: Patients with elective coronary artery bypass grafting with LV systolic dysfunction (EF LV ≤ 50%) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006889-29 | Sponsor Protocol Number: MEC-2008-322 | Start Date*: 2009-02-25 |
Sponsor Name:ErasmusMC | ||
Full Title: A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors. | ||
Medical condition: Uptake of Octreoscan in sst-2 receptor positive Gastro Entero Pancreatic neuroendocrine tumors injected in systemical and locoregional way. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005609-21 | Sponsor Protocol Number: RAD50 | Start Date*: 2009-08-03 | |||||||||||
Sponsor Name:Faculty For Medicine, Otto-von-Guericke University Magdeburg | |||||||||||||
Full Title: Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors. | |||||||||||||
Medical condition: In addition to the assessment of shunt volumes, the intrahepatic distribution of MAA may allow for prediction of tumor radiation dose and the radiation dose to normal liver tissue. Even though MAA ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001472-18 | Sponsor Protocol Number: UDT-2/PHT | Start Date*: 2011-05-10 |
Sponsor Name:STZ 1172 Gesundheitsförderung und Stoffwechselforschung | ||
Full Title: Double-Blind, Randomised, Cross-Over, Placebo-Controlled, Single-Centre Phase IIa Clinical Study on the Influence of Udenafil on the Portal Flow in Cirrhotic Patients with Portal Hypertension | ||
Medical condition: Portal hypertension, liver cirrhosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001222-83 | Sponsor Protocol Number: HHSC/001 | Start Date*: 2005-12-09 | ||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||
Full Title: A phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haemopoietic stem cells to patients with liver insufficiency | ||||||||||||||||||
Medical condition: Chronic liver insufficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000270-28 | Sponsor Protocol Number: NL75171.058.20 | Start Date*: 2022-06-30 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study | ||
Medical condition: Hepatocellular carcinoma, hepatic adenoma, intrahepatic cholangiocarcinoma, colorectal liver metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022660-12 | Sponsor Protocol Number: PRAISE_ZKS0006 | Start Date*: 2011-02-02 | |||||||||||
Sponsor Name:Friedrich Schiller University | |||||||||||||
Full Title: A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation | |||||||||||||
Medical condition: the early postoperative period after liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004859-22 | Sponsor Protocol Number: UF9888 | Start Date*: 2018-04-12 | |||||||||||
Sponsor Name:University Hospital of Monptellier | |||||||||||||
Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study | |||||||||||||
Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004632-24 | Sponsor Protocol Number: | Start Date*: 2008-02-01 |
Sponsor Name:ARTBC | ||
Full Title: OPTIMAL CONTROL OF LIVER METASTASES WITH INTRAVENOUS CETUXIMAB AND HEPATIC ARTERY INFUSION OF THREE-DRUG CHEMOTHERAPY IN PATIENTS WITH LIVER-ONLY METASTASES FROM COLORECTAL CANCER. A PHASE II TRIAL | ||
Medical condition: The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetux... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) PT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000236-26 | Sponsor Protocol Number: CRLX030X2201 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension | |||||||||||||
Medical condition: Compensated alcohol-related cirrhosis and portal hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008754-23 | Sponsor Protocol Number: CILT08 | Start Date*: 2009-12-16 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Göttingen | ||||||||||||||||||||||||||||
Full Title: A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation. | ||||||||||||||||||||||||||||
Medical condition: Patients with renal dysfunction undergoing liver transplantation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005405-78 | Sponsor Protocol Number: 2011430 | Start Date*: 2012-02-01 | ||||||||||||||||
Sponsor Name:Steen Bendix Haugaard | ||||||||||||||||||
Full Title: Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes | ||||||||||||||||||
Medical condition: Patients suffering of both Type 2 diabetes mellitus and coronary artery disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004987-91 | Sponsor Protocol Number: 2020/ABM/01/00098 | Start Date*: 2021-11-17 | |||||||||||
Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu | |||||||||||||
Full Title: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic can... | |||||||||||||
Medical condition: Unresectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006393-14 | Sponsor Protocol Number: UDT-1/PHT | Start Date*: 2007-10-23 | ||||||||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | ||||||||||||||||||
Full Title: Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypert... | ||||||||||||||||||
Medical condition: Portal hypertension, liver cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) LT (Completed) CZ (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003059-36 | Sponsor Protocol Number: Bay 58-2667/12480 | Start Date*: 2007-12-10 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with acute deco... | |||||||||||||
Medical condition: Patients with acute decompensated chronic congested heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001493-15 | Sponsor Protocol Number: UC-0110/1610 | Start Date*: 2017-10-13 |
Sponsor Name:UNICANCER | ||
Full Title: A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only col... | ||
Medical condition: Patients with liver-only non resectable colorectal metastases. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002661-35 | Sponsor Protocol Number: FERRICCABG01 | Start Date*: 2020-04-23 | ||||||||||||||||
Sponsor Name:King's College London
[...]
1. King's College London
2. King's College Hospital NHS Foundation Trust |
||||||||||||||||||
Full Title: Effect of Iron Isomaltoside on Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Graft ± Valve Surgery: The Ferric Iron in Coronary Artery Bypass Grafting (FERRIC-CABG) ... | ||||||||||||||||||
Medical condition: Coronary or heart valve disease needing cardiac surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000417-44 | Sponsor Protocol Number: PHP-OCM-301A | Start Date*: 2016-03-31 | |||||||||||
Sponsor Name:Delcath Systems, Inc | |||||||||||||
Full Title: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma. | |||||||||||||
Medical condition: Hepatic-Dominant Ocular Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002330-23 | Sponsor Protocol Number: 9794 | Start Date*: 2017-11-24 | |||||||||||
Sponsor Name:University hospital of Montpellier | |||||||||||||
Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY | |||||||||||||
Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
